Vaxdyn
Developing vaccines to prevent antibiotic-resistant infections.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €12.0m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (68 %) | 2762 % | 97 % | (98 %) | (73 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 277 % | 154 % | 94 % | 79 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (39 %) | 47 % | 4 % | 24 % | 983 % | 4784 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Vaxdyn is a biotechnology company dedicated to developing vaccines that target multi-drug resistant bacteria, addressing a critical global health crisis. The company focuses on creating inactivated, endotoxin-free whole cell vaccines that display multiple conserved antigens from pathogens like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. These vaccines aim to establish protective immunity against some of the most dangerous antibiotic-resistant bacteria. Vaxdyn serves healthcare providers and patients in urgent need of new solutions to combat antibiotic-resistant infections. Operating in the biotech and pharmaceutical markets, Vaxdyn's business model revolves around extensive research and development, clinical trials, and eventual commercialization of their vaccine candidates. The company generates revenue through funding from international collaborations, grants, and future sales of their patented vaccine products.
Keywords: multi-drug resistant, vaccines, biotechnology, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, endotoxin-free, conserved antigens, global health, antibiotic-resistant.